Suven Life Sciences to present Phase-2 Positive Results on Samelisant at American Academy of Neurology2024 Annual Meeting, Denver, USA

Following up to the topline results disclosure earlier, the scientific session scheduled at AAN2024 will provide the comprehensive findings from the Phase-2 study.

Discussions with Key Opinion Leaders (KOL) and Principle Investigators (PI) at AAN-2024 to finalize the study design for the global Phase-3 study.

Global Phase-3 study initiation expected in the second half of 2024.

Exhibit booth # 742 at AAN-202 is showcasing the Innovations pipeline of Suven Life.

Suven Life Sciences, a clinical-stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, announced today scientific presentation at the upcoming 76th American Academy of Neurology (AAN) annual meeting being held April 13-18, 2024, in Denver, USA and virtually. The AAN Annual Meeting is the world's largest gathering of neurologists and neuroscience professionals and offers top-tier education and the latest in scientific discoveries, clinical updates, and many more from around the globe.

Suven's scientific presentation at AAN will highlight details of the positive study results from its Phase-2 proof-of-concept study assessing the safety and efficacy of samelisant for the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. The study met primary endpoint, with samelisant demonstrating statistically significant and clinically meaningful reduction in EDS measured by the Epworth Sleepiness Scale (ESS) total score compared to placebo at Day 14 (p<0.05). Highly statistically significant effects were observed against placebo for the other efficacy endpoints related to EDS like Clinical Global Impression of Severity (CGI-S) score, Patient Global Impression-Change (PGIC), and Clinical Global Impression of Change (CGI-C).

AAN 2024 Presentation Details:

Title: Samelisant (SUVN-G3031) - Clinical efficacy and safety outcome from the Phase-2 Proofof-Concept Double-blind, Placebo-controlled Study in Patients with Narcolepsy. Presentation on Wednesday, April 17, 2024.

Team of Chief Scientists from Suven will meet several Key Opinion Leaders (KOL), Principle Investigators (PI), Medical and Regulatory advisors at AAN-2024 to discuss the global Phase3 study design to evaluate Samelisant for the treatment of EDS in adult Narcolepsy patients with and without cataplexy. Global Phase-3 study initiation is expected in the second half of 2024.

Suven is showcasing its innovations pipeline and comprehensive summaries at AAN 2024 with an exhibit booth # 742.

Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 112.20 as compared to the previous close of Rs. 114.46. The total number of shares traded during the day was 13287 in over 155 trades.

The stock hit an intraday high of Rs. 116.50 and intraday low of 108.74. The net turnover during the day was Rs. 1473058.00.

Source : Equity Bulls

Keywords

SuvenLifeSciences INE495B01038 Phase2 PositiveResults